IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Reviva Pharmaceuticals Holdi (RVPH)

CUSIP: 76152G100 | NYSE | Healthcare · Biotechnology | Micro Cap | 120 institutional holders

Quarters

Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13D/AParag Saxena
with Vedanta Partners, LLC
6,268,0065.2%+8,200Dec 18, 2025No 13F filer matched
13D/ABhat Laxminarayan3,680,8743.8%Newly reportedSep 22, 2025No 13F filer matched
13D/AParag Saxena6,268,006
5.2% of class · Dec 18, 2025+8,200
with Vedanta Partners, LLC
No 13F filer matched
13D/ABhat Laxminarayan3,680,874
3.8% of class · Sep 22, 2025Newly reported
No 13F filer matched

Institutional Holders — Q1 2026

IFP Advisors, Inc4,000
0.0% of portfolio›$714
Vanguard Group Inc0
0.0% of portfolio›$0
StyleTurnoverLocationFiled
IFP Advisors, Inc
4,000$7140.0%GrowthLowTampa, FL2026-04-13
Vanguard Group Inc
0$00.0%N/AN/AValley Forge, PA2026-05-14